Gastrointestinal Cancer News

A novel risk-stratification model developed for noninvasive identification of T1 colorectal cancer may help avoid unnecessary surgeries for high-risk patients.

Individuals preferred stool-based screening for colorectal cancer over colonoscopy, according to survey results published in Cancer Prevention Research.

Technology-enabled symptom monitoring in conjunction with nurse practitioner follow-up provided responsive care to patients with cancer during the COVID-19 pandemic, according to study results.

The FDA granted breakthrough therapy designation to bemarituzumab for use with chemotherapy as first-line treatment of certain patients with gastrointestinal cancers, according to the agent’s manufacturer.

Patients with perianal Crohn’s disease had worsened disease outcomes compared with patients with Crohn’s disease alone, according to research published in Clinical Gastroenterology and Hepatology.

More than one-third of a small cohort patients with early-stage hepatocellular carcinoma achieved at least 50% tumor necrosis following neoadjuvant treatment with cemiplimab, results of a phase 2a trial showed.

The FDA approved nivolumab as part of combination therapy for certain patients with gastrointestinal malignancies.

Primary tumor resection before chemotherapy did not improve OS compared with chemotherapy alone among patients with unresectable stage IV colorectal cancer, according to phase 3 study results published in Journal of Clinical Oncology.

Black patients with early-onset, microsatellite-stable colorectal cancer had substantially higher tumor mutational burden than their white counterparts, according to study results.

Increased use of fecal immunochemical testing correlated with more colorectal cancer screenings and early-stage diagnoses amid the COVID-19 pandemic, according to research in JAMA Network Open.